CD274 and melanoma: Stimulation of the adaptive immune response using immune checkpoint inhibitor (ICI) drugs has revolutionized treatment for melanoma, lung, bladder, and renal cancers.2 The clinically approved ICI drugs target two classes of lymphocyte inhibitory pathways (CTLA-4, PD-1/PD-L1), which are particularly important in regulating priming and activation of T cells.